Nicotinamide phosphoribosyltransferase inhibits receptor activator of nuclear factor-κB ligand-induced osteoclast differentiation in vitro

被引:25
|
作者
Baek, Jong Min [1 ]
Ahn, Sung-Jun [1 ]
Cheon, Yoon-Hee [2 ]
Lee, Myeung Su [3 ,5 ]
Oh, Jaemin [1 ,4 ,5 ]
Kim, Ju-Young [4 ]
机构
[1] Wonkwang Univ, Dept Anat, 344-2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea
[2] Wonkwang Univ, Ctr Metab Funct Regulat, Iksan 570749, South Korea
[3] Wonkwang Univ, Dept Internal Med, Div Rheumatol, Iksan 570749, South Korea
[4] Wonkwang Univ, Imaging Sci Based Lung & Bone Dis Res Ctr, 344-2 Sinyong Dong, Iksan 570749, Jeonbuk, South Korea
[5] Wonkwang Univ, Inst Skeletal Dis, Iksan 570749, Jeonbuk, South Korea
基金
新加坡国家研究基金会;
关键词
nicotinamide phosphoribosyltransferase; adipokine; osteoclast; osteoporosis; COLONY-ENHANCING FACTOR; CELLS; RANKL; BIOSYNTHESIS; PATHWAYS; PROTEINS; SURVIVAL; SIGNALS; MICE; FOS;
D O I
10.3892/mmr.2016.6069
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The adipokine nicotinamide phosphoribosyltransferase (Nampt), also known as pre-B-cell colony-enhancing factor or the insulin-mimetic hormone visfatin, has a crucial role in the conversion of nicotinamide to nicotinamide mono nucleotide during biosynthesis of the coenzyme nicotinamide adenine dinucleotide. Previous reports have demonstrated the inhibitory effects of Nampt on osteoclast formation from human peripheral blood mononuclear cells and CD14(+) monocytes. However, the effects of Nampt on bone marrow macrophage (BMM)-derived osteoclastogenesis and its precise role in the process remain unclear. The present in vitro study used recombinant Nampt and BMMs as osteoclast precursors demonstrated that Nampt suppresses receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclastogenesis by decreasing the phosphorylation of various early signal transducers, including c-Jun N-terminal kinase, Akt, glycogen synthase kinase-3 beta, Bruton's tyrosine kinase and phospholipase C gamma-2. In addition, western blotting and reverse transcription-quantitative polymerase chain reaction analysis indicated that Nampt downregulates the mRNA and protein expression levels of c-Fos and nuclear factor of activated T cells, cytoplasmic 1, leading to a decrease in the expression of osteoclast-specific genes including tartrate-resistant acid phosphatase, osteoclast-associated receptor and cathepsin K. However, the bone-resorbing activity of mature osteoclasts treated with Nampt was similar to untreated control osteoclasts. This finding indicates that Nampt exerts its anti-osteoclastogenic activity by targeting osteoclast precursor cells rather than mature osteoclasts. Consequently, the present study demonstrated that Nampt acts as a negative regulator of RANKL-mediated differentiation of BMMs into osteoclasts, suggesting the potential therapeutic targets to treat bone-related disorders such as osteoporosis.
引用
收藏
页码:784 / 792
页数:9
相关论文
共 50 条
  • [41] Eleutherococcus sessiliflorus Inhibits Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL)-Induced Osteoclast Differentiation and Prevents Ovariectomy (OVX)-Induced Bone Loss
    Han, Sang-Yong
    Kim, June-Hyun
    Jo, Eun-Heui
    Kim, Yun-Kyung
    MOLECULES, 2021, 26 (07):
  • [42] Inhibitory effect of serum amyloid A on receptor activation of nuclear factor κB ligand-induced osteoclast formation
    Bae, Yoe-Sik
    Oh, Eunseo
    Lee, Ha Young
    Kim, Hak Jung
    Park, Yoo Jung
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [43] Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo
    Baek, Jong Min
    Kim, Ju-Young
    Yoon, Kwon-Ha
    Oh, Jaemin
    Lee, Myeung Su
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2016, 12 (05): : 478 - 488
  • [44] EBSELEN IS A POTENTIAL ANTI-OSTEOPOROSIS AGENT BY SUPPRESSING RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B LIGAND-INDUCED OSTEOCLAST DIFFERENTIATION IN VITRO AND LIPOPOLYSACCHARIDE-INDUCED INFLAMMATORY BONE DESTRUCTION IN VIVO
    Baek, J. M.
    Kim, J. -Y.
    Yoon, K. -H.
    Oh, J.
    Lee, C. -H.
    Lee, M. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 82 - 83
  • [45] Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis
    Takayanagi, H
    Iizuka, H
    Juji, T
    Nakagawa, T
    Yamamoto, A
    Miyazaki, T
    Koshihara, Y
    Oda, H
    Nakamura, K
    Tanaka, S
    ARTHRITIS AND RHEUMATISM, 2000, 43 (02): : 259 - 269
  • [46] IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-κB ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage
    Khapli, SM
    Mangashetti, LS
    Yogesha, SD
    Wani, MR
    JOURNAL OF IMMUNOLOGY, 2003, 171 (01): : 142 - 151
  • [47] Protocatechualdehyde inhibits receptor activator of nuclear factor kappa-B ligand-induced osteoclastogenesis and attenuates lipopolysaccharide-induced inflammatory osteolysis
    Huang, Hao
    Jiang, Wenli
    Hong, Kehua
    Cai, Jie
    He, Yongchao
    Ma, Xuming
    Wu, Peng
    Lang, Junzhe
    Ma, Yuegang
    Huang, Caiguo
    Yuan, Jiandong
    PHYTOTHERAPY RESEARCH, 2021, 35 (07) : 3821 - 3835
  • [48] Interleukin-1 induces receptor activator of nuclear factor-κB ligand-independent osteoclast differentiation in RAW264.7 cells
    Liao, Rongdong
    Feng, Zhuoxi
    Li, Wei
    Liu, Rubing
    Xu, Xinrou
    Yao, Shun
    Tian, Jing
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (06)
  • [49] Requirement for nuclear Factor-κB activation in osteoclast differentiation induced by RANK ligand (RANK-L).
    Wei, S
    Teitelbaum, SL
    Wang, MWH
    Ross, FP
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S391 - S391
  • [50] The Effect of Osteoprotegerin (OPG)/Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) on Aortic Valve Calcified
    Luo, Wei
    Wang, Jing
    Yang, Xia
    Li, Junshan
    Song, Yanqiu
    Cong, Hongliang
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2024, 54 (05): : 633 - 642